12 Month Price Forecast For CYBN
Distance to CYBN Price Forecasts
CYBN Price Momentum
๐ค Considering Cybin (CYBN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 10:03 AM UTC
CYBN Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, CYBN has a consensus that is bullish. The median price target is $98.39, with forecasts ranging from $24.58 to $190.54. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CYBN currently trading at $9.00, the median price forecast suggests a 993.2% upside. The most optimistic forecast comes from at , projecting a 2,017.1% upside, while at provides the most conservative target, suggesting a 173.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CYBN Analyst Consensus
CYBN Price Target Range
Latest CYBN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CYBN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 27, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $190.00 |
Nov 19, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $86.00 |
Nov 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $190.00 |
Nov 18, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $190.00 |
Nov 14, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $86.00 |
Sep 23, 2024 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $96.00 |
Aug 23, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
Jul 31, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
Jul 31, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
Jun 21, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
May 16, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
Mar 13, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
Feb 15, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
Nov 17, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
Oct 31, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
Sep 1, 2023 | Canaccord Genuity | Sumant Kulkarni | Buy | Reiterates | $5.00 |
Aug 30, 2023 | Oppenheimer | Francois Brisebois | Outperform | Reiterates | $4.00 |
Aug 29, 2023 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $3.00 |
Aug 29, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $10.00 |
Aug 22, 2023 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $3.00 |
Stocks Similar to Cybin Inc.
The following stocks are similar to Cybin based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cybin Inc. (CYBN) Financial Data
Cybin Inc. has a market capitalization of $187.40M with a P/E ratio of -0.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -49.1%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Cybin Inc. (CYBN) Company Overview
About Cybin Inc.
Develops psychedelic-based therapeutics for mental health.
Cybin Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of psychedelic-based therapeutics. It generates revenue by advancing its drug candidates through clinical trials and forming strategic partnerships for research and development, as well as potential commercialization of its therapies.
The company's pipeline includes several compounds in various stages of clinical trials aimed at treating conditions such as major depressive disorder and generalized anxiety disorders. Additionally, Cybin has established collaborations with organizations like TMS Neurohealth Centers and Kernel to enhance its research capabilities and develop innovative treatment solutions. Headquartered in Toronto, Canada, Cybin is positioned at the forefront of the emerging psychedelic therapy market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
50
CEO
Country
Canada
IPO Year
2019
Website
www.cybin.comCybin Inc. (CYBN) Latest News & Analysis
Wall Street Analysts Believe Cybin Inc. (CYBN) Could Rally 952.23%: Here's is How to Trade
9 days agoWall Street analysts' price targets suggest a potential upside of 952.2% for Cybin Inc. (CYBN), supported by positive earnings estimate revisions.
A 952.2% price target upside for Cybin Inc. suggests significant growth potential, while positive earnings revisions may enhance investor confidence and drive stock performance.
Cybin Inc. has launched a strategic partnership with Segal Trials to advance its Phase 3 program for CYB003, aimed at treating Major Depressive Disorder.
Cybin's partnership with Segal Trials enhances its Phase 3 program for CYB003, signaling progress in mental healthcare innovations, potentially boosting investor confidence and stock performance.
Cybin Inc. (NYSE American: CYBN) reported significant progress in 2024 towards revolutionizing mental healthcare and outlined upcoming milestones for 2025.
Cybin's advancements in neuropsychiatry and its commitment to innovative treatments could enhance its market position, potentially influencing stock performance and investor sentiment.
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
29 days agoCybin Inc. CEO Doug Drysdale will participate in a virtual fireside chat at the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025.
Cybin's CEO participation in a healthcare summit highlights its commitment to innovation in mental health, potentially influencing investor confidence and interest in its growth prospects.
Cybin Inc. will present two posters at the ACNP Annual Meeting from December 8-11, 2024, showcasing 12-month efficacy results for its innovative mental healthcare treatments.
Cybin's presentation at a key conference highlights progress in mental health treatments, potentially boosting investor confidence and interest in its innovative therapies.
Cybin Inc. (NYSE: CYBN) executives will join the Water Tower Research Fireside Chat Series, highlighting their focus on innovative mental healthcare solutions.
Cybin's participation in the Fireside Chat Series signals transparency and engagement, potentially boosting investor confidence and highlighting its commitment to mental healthcare innovation.
Frequently Asked Questions About CYBN Stock
What is Cybin Inc.'s (CYBN) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Cybin Inc. (CYBN) has a median price target of $98.39. The highest price target is $190.54 and the lowest is $24.58.
Is CYBN stock a good investment in 2025?
According to current analyst ratings, CYBN has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CYBN stock?
Wall Street analysts predict CYBN stock could reach $98.39 in the next 12 months. This represents a 993.2% increase from the current price of $9.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cybin Inc.'s business model?
Cybin Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of psychedelic-based therapeutics. It generates revenue by advancing its drug candidates through clinical trials and forming strategic partnerships for research and development, as well as potential commercialization of its therapies.
What is the highest forecasted price for CYBN Cybin Inc.?
The highest price target for CYBN is $190.54 from at , which represents a 2,017.1% increase from the current price of $9.00.
What is the lowest forecasted price for CYBN Cybin Inc.?
The lowest price target for CYBN is $24.58 from at , which represents a 173.1% increase from the current price of $9.00.
What is the overall CYBN consensus from analysts for Cybin Inc.?
The overall analyst consensus for CYBN is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $98.39.
How accurate are CYBN stock price projections?
Stock price projections, including those for Cybin Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.